Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adiantum capillus-veneris hydroalcoholic extract is a botanical research compound derived from the maidenhair fern (*Adiantum capillus-veneris*). It is prepared using a water-alcohol (hydroalcoholic) extraction method, which concentrates a complex profile of bioactive secondary metabolites, including flavonoids (such as rutin, quercetin, and kaempferol), phenolic acids, triterpenoids, saponins, and tannins. Preclinical research in animal models has demonstrated that the extract possesses a range of pharmacological activities, including anti-inflammatory, antioxidant, antimicrobial, and antidiabetic effects. Specifically, studies have investigated its potential therapeutic utility in treating conditions such as ulcerative colitis, depression, anxiety, oxidative stress, and urolithiasis. It is currently classified as a natural product or botanical extract used in traditional medicine research rather than a targeted pharmaceutical development program, and there is no specific commercial sponsor or defined single biological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adiantum capillus-veneris hydroalcoholic extract.